Table 1. **Patient characteristics**

	Overall cohort (n=251)	Tangential clamping (n=133)	Non tangential clamping (n=118)	P value
Age (years)	68 (61-74)	66 (59-73)	69 (64-75)	0.0095
Sex, male, n (%)	217 (86%)	119 (89%)	98 (83%)	0.1
Height (cm)	169±10	169±11	169±7	0.86
Weight (kg)	76±12	76±13	76±12	0.7
Smoking, n (%)	103 (41%)	62 (47%)	41 (35%)	0.056
Family history of CAD	61 (24%)	30 (23%)	31 (26%)	0.49
Systemic arterial hypertension, n (%)	152 (61%)	78 (59%)	74 (63%)	0.51
Hypercholesterolemia, n (%)	179 (71%)	97 (73%)	82 (69%)	0.55
Diabetes, n (%)	85 (34%)	41 (34%)	44 (33%)	0.78
Peripheral vascular disease, n (%)	45 (18%)	21 (16%)	24 (20%)	0.35
Cerebrovascular disease, n (%)	35 (14%)	14 (11%)	21 (18%)	0.097
Most recent serum creatinine prior surgery (mg/dl)	1.02±0.35	1.02±0.38	1.01±0.31	0.78
Euroscore 1	4 (2-6)	4 (1-6)	4 (2-6)	0.38
NYHA class, n (%)*				0.60
I	19 (8%)	12 (10%)	7 (6%)	
II	188 (81%)	96 (78%)	92 (84%)	
III	22 (9%)	12 (10%)	10 (9%)	
IV	4 (2%)	3 (2%)	1 (1%)	
Unstable angina, n (%)	20 (8%)	10 (8%)	10 (8%)	0.78

Therapy prior surgery, n (%)			
Calcium antagonist	49 (20%)	20 (15%)	29 (25%)	0.057
Beta-blocker	144 (57%)	78 (59%)	66 (56%)	0.664
ACE inhibitor/ARB	105 (42%)	49 (37%)	56 (47%)	0.089
Nitrates	19 (8%)	14 (11%)	5 (4%)	0.06
Aspirin	74 (29%)	45 (34%)	29 (25%)	0.108
Diuretics	37 (15%)	12 (9%)	25 (22%)	0.007
LV EF (%)	60 (52-64)	59 (51-62)	60 (53-65)	0.14
Prior PCI, n (%)	40 (16%)	21 (16%)	19 (16%)	0.95

Values are n (%), mean±SD or median, 1st-3rd quartile range.

ACE= Angiotensin Converting Enzyme; ARB= Angiotensin II Receptor Blocker; CAD= coronary

artery; disease; NYHA= New York Heart Association; PCI= Percutaneous Coronary Intervention.

* Unknown NYHA class in 18 patients.